TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04478838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg Tablets
Study: NCT05709665

Intervention type: OTHER
Intervention: Time to Decision for eCPR
Description: We evaluate during high quality CPR the time for decision for eCPR

Intervention type: OTHER
Intervention: Time to Decision for eCPR
Description: We evaluate during high quality CPR the time for decision for eCPR
Study: NCT04332263

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation - NMES
Description: NMES will be applied through an alternating biphasic current, with a stimulation frequency of 80 Hz and 1 ms pulse duration. Tetanic evoke forces (EF) at a 50% level of a supra-maximal single-pulse peak EF (i.e., 10-12% of a maximal voluntary isometric contraction) will be used. NMES protocol will be performed five times a week, lasting 20 minutes. Muscle fatigue will be evaluated every 5 min of the intervention, and will be used to determine the NMES protocol termination. A 10 % decrease in the single-pulse evoked torque between the evoked force produced pre- and during the NMES protocol will be used to terminate the fatigue protocol.
Study: NCT04999241

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: exclusive enteral nutrition
Description: Administration of a liquid formula diet with the exclusion of all other regular food for 8 weeks, then patients can administration of regular food.

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: regular food
Description: Administration of regular food in the induction phase and the later time.
Study: NCT05263362

Intervention type: OTHER
Intervention: no intervention
Description: At one timepoint patients will get physical examination of the breasts, medical photographs will be taken, and they will fill in five questionnaires about satisfaction of the breasts, quality of life and general health.
Study: NCT06323759

Intervention type: OTHER
Group type: OTHER
Intervention: educational intervention
Description: In antenatal breastfeeding education: Theoretical contributions on BF (physiology of lactation, frequency complications), hands-on workshop, Provision of educational tools to promote the learning environment: breastfeeding booklet, educational video on breastfeeding, link to a BF specific platform, access to a telephone platform. In short-term postnatal breastfeeding education: Three systematic fallow-up at home or at midwives' office are planned. During these visits, a time of systematic discussion is planned with the nursing mothers. Their knowledge and ability to manage their breastfeeding are checked. The physiology of lactation, the gestures of breastfeeding and the occurrence of common complications are systematically recalled by the liberal midwife. In long-term postnatal breastfeeding education: Invitation of nursing mothers to breastfeeding information meetings at 2nd and 4th month after birth. These meetings will be facilitated either by the liberal midwives.
Study: NCT05013411

Intervention type: OTHER
Intervention: Qualitative study
Description: Individual interviews and focus groups will be conducted to explore current strengthens and barriers in obtaining patient observations. Views on use of technology in assisting with patient observations will also be discussed and documented.
Study: NCT06235671

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic care
Description: 6 weeks of chiropractic care
Study: NCT04768088

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Falling Training
Description: For the falling training, participants will be instructed to initially land softly with increased knee and hip flexion and then smoothly fall to the direction of the movement while transferring the weight from the feet to the hands and subsequently to the lateral trunk and hip. The training program includes three one-hour training sessions over a week with one or two days between two sessions. Each training session will begin with a warm-up protocol. Participants will progressively increase the task difficulty and decrease the thickness of the mat. For each training session, participants will perform a minimum of one successful practice trial for each task difficulty and each landing direction on the thicker mat and then complete a minimum of three successful practice trials for each task difficulty and landing direction on the thinner mat. The last training session involves falling on a 0.5-inch mat, which is the same as the surface for the post-training and retention assessments.
Study: NCT04654013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Intervention group workers receive free glasses within one week of undergoing vision assessment (May 2022). The duration of the treatment for the Intervention participants will depend on when they leave employment at the factor. If they stayed for the full duration of the trial, they will have undergone a maximum of 18 months (December 2023).
Study: NCT04284254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Plasmablasts
Description: Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~* Dose Level 1: 5 x 10e7 cells/kg on Day 0~* Dose Level 2: 1 x 10e8 cells/kg on Day 0~* Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~- Maximum Tolerated Dose (MTD) established in Phase I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Autologous Plasmablasts
Description: Autologous Plasmablasts engineered to express α-L-iduronidase (IDUA) using the Sleeping Beauty transposon system.~Phase 1:~* Dose Level 1: 5 x 10e7 cells/kg on Day 0~* Dose Level 2: 1 x 10e8 cells/kg on Day 0~* Dose Level 3: 1 x 10e8 cells/kg x 2 doses on Day 0 and Day 30 +/-3 days.~Phase 2:~- Maximum Tolerated Dose (MTD) established in Phase I
Study: NCT05789966

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic Risk Estimate+Health Coaching
Description: The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' (if their genetic risk is higher than the average population risk) or 'no increased genetic risk' (if their genetic risk is not higher than the average population risk). Health coaching will be incorporated through phone or Zoom calls to provide an explanation of each participant's own genetic risk of CHD as well as lifestyle modification measures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genetic Risk Estimate + Fitbit Functions+Health Coaching
Description: Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Genetic Risk Estimate + Fitbit Functions+Health Coaching
Description: Intervention: Device: Genetic Risk Estimate + Fitbit Functions The genetic risk information includes individual remaining-lifetime and 10-year genetic risk estimates for CHD as well as a dichotomized genetic risk category: 'increased genetic risk' or 'no increased genetic risk'.~The two unique Fitbit functions are step goal setting and prompts. Individualized daily step goals will be set to be 10% higher than participants' own baseline Fitbit step counts. The 'Reminder To Move' function of Fitbit will be used as a prompt to remind participants to reduce sedentary time and walk at least 250 steps/hour within a specified timeframe (i.e., from 9am to 10pm in the proposed research). If the user has not accumulated at least 250 steps/hour, a reminder (for example, 150 steps to go) will appear on the Fitbit screen at 10 minutes before the hour (for example, at 10:50 a.m.) and cause the device to vibrate. Health coaching will be incorporated as well
Study: NCT06521177

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Serum and Glove
Description: Participants will apply the Hand Serum to both hands daily for 8 weeks. During Weeks 7-8, participants will also wear a glove on one hand. The intervention aims to improve skin health and appearance on the hands, assessed through questionnaires and expert skin grading.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Serum and Glove
Description: Participants will apply the Hand Serum to both hands daily for 8 weeks. During Weeks 7-8, participants will also wear a glove on one hand. The intervention aims to improve skin health and appearance on the hands, assessed through questionnaires and expert skin grading.
Study: NCT05376501

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: 8 mg Astaxanthin per capsule, taken once a day with meal

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Modified food starch
Study: NCT06492083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional Chinese medicine hot bag
Description: traditional Chinese medicine hot bag
Study: NCT05867381

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA filtration
Description: HEPA filters with the capacity to reduce PM2.5 levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HEPA filtration
Description: HEPA filters with the capacity to reduce PM2.5 levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham filtration
Description: Sham filtration use the same appearance of air purifier but with HEPA filter removed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham filtration
Description: Sham filtration use the same appearance of air purifier but with HEPA filter removed.
Study: NCT05327582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Administered intravenously, 1000 mg on day 1 in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Administered orally, 8mg/d once daily in a 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Administered intravenously, 180-220 mg/m2 on day1 in a 3-week cycle
Study: NCT05273762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowTriever
Description: Mechanical thrombectomy for pulmonary embolism
Study: NCT05567081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide 40mg/mL
Description: Deep perineural injection with 1cm corticosteroid mixed with 1ml lidocaine hydrochloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: Deep perineural injection with 3ml PRP at the thickest part of the ulnar nerve.
Study: NCT06138210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exosomes derived from human induced pluripotent stem cell for injection
Description: Exosomes derived from human induced pluripotent stem cell for injection (3.0ml, 1×10\^11particles/ml).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a placebo of exosomes derived from human induced pluripotent stem cell for injection
Description: Exosomes placebo, 3.0ml
Study: NCT04352673

Intervention type: DIAGNOSTIC_TEST
Intervention: Elbow flexion and extension strength measurements using a hand-held dynamometer
Description: Elbow flexion and extension strength of the participants will be measured in both arms in the supine, prone, and sitting positions using a hand-held dynamometer.
Study: NCT05804812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: laughter therapy
Description: Assigned Interventions Laughter therapy session will be applied online for 25-30 minutes once a week for 2 months by the researcher who has the Laughter therapy certificate to the application group. In the laughter therapy session, the practices of introducing the practitioner and introducing the therapy, breathing exercises for a healthy life, keeping the rhythm accompanied by music, turning the laughter that started as if it were childlike games into reality will be carried out.
Study: NCT04624113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Epizyme will supply the study agent, which will be provided free of charge to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: Epizyme will supply the study agent, which will be provided free of charge to the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is commercially available

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is commercially available
Study: NCT06144515

Intervention type: PROCEDURE
Intervention: Blood test
Description: Blood is collected in order to perform in vitro research:~1. If a routine blood test is performed for clinical tests, the sponsor will receive the results of the Complete blood count (CBC) and an additional blood sample from the same puncture of 20ml to maximum 40ml will be collected for this study.~2. If no routine blood test is performed for clinical tests, a CBC will be performed for the study and an additional blood sample of 20ml to maximum 40ml will be collected.~Additional Bone marrow (BM) material will be obtained from the same puncture performed for routine clinical tests:
Study: NCT06368310

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INBRAIN Graphene Cortical Interface
Description: Study device to be evaluated intra-operatively alongside standard of care neurophysiological monitoring.
Study: NCT06114680

Intervention type: DEVICE
Group type: OTHER
Intervention: CochSyn test prototype
Description: The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.

Intervention type: DEVICE
Group type: OTHER
Intervention: CochSyn test prototype
Description: The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.

Intervention type: DEVICE
Group type: OTHER
Intervention: CochSyn test prototype
Description: The CochSyn test prototype is intended for use in the evaluation of hearing-related disorders in adults using auditory evoked potentials. The CochSyn test prototype records biopotential waveforms that can be used for hearing screening and diagnostic applications.

Intervention type: DEVICE
Group type: OTHER
Intervention: Universal Smart Box (USB)
Description: Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.

Intervention type: DEVICE
Group type: OTHER
Intervention: Universal Smart Box (USB)
Description: Commercially available EEG system intended for use in the diagnosis of hearing related disorders, hearing threshold detection, and other conditions that may affect the responses to auditory, tactile, or visual stimuli. The USB Box hardware and accompanying software programs can be used with patients of all ages. It is intended for use by trained personnel in a hospital, nursery, clinic, audiologist's office, or other appropriate setting.
Study: NCT06401707

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel
Description: Perampanel is a non-competitive AMPA glutamate receptor antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05337761

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Peer-led training on lifejacket wear
Description: Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-led training on lifejacket wear
Description: Training on proper lifejacket wear will be given to peers who will be the change agents amongst their fellow boaters
Study: NCT05211934

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05074966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: mXELOX plus cetuximab
Description: Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Cetuximab: 500 mg/m2, IV, d1, q2w; Oxaliplatin: 85 mg/m2, IV, d1,q2w; Capecitabine: 850 mg/m2, po, bid, q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Capecitabine: 850 mg/m2, po, bid, d1-10, q2w;

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: FOLFOX plus cetuximab
Description: Patients will receive the study drug after randomization, and those with effective efficacy evaluation (CR, PR or SD) will receive intravenous chemotherapy for up to 9 cycles, and then enter the maintenance treatment stage until PD, death, intolerable toxicity or withdrawal of informed consent (whichever occurs first)~Oxaliplatin 85 mg/m2, IV d1; Leucovorin 400 mg/m2 IV d1; 5-FU 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48 hours) IV continuous infusion; q2w maintenance stage: Cetuximab: 500 mg/m2, IV, d1, q2w; Leucovorin： 400 mg/m2 IV d1, q2w; 5-FU： 400 mg/m2 IV bolus on d1, then 1200 mg/m2/d x 2d(total 2400 mg/m2 over 46-48hours) IV continuous infusion, q2w （Cetuximab combined with capecitabine can be used according to the patient's wishes and the nursing situation of intravenous catheterization）
Study: NCT04844216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® L Lidocaine
Description: An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: An injection of maximum 2 mL on one nasolabial fold is planned at Day 0. A touch-up of maximum 1 mL on the same nasolabial fold is possible 1 month after D0 (month 1).
Study: NCT05286892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes LIVE JustICE
Description: Diabetes LIVE JustICE will be an adaptation of the current Diabetes LIVE persistent multi-user online virtual environment built on the Unreal Engine (Epic Games, Inc., Cary, NC) that allows users to talk to each other in real-time and participate in instructor-led synchronous sessions. Users can access the virtual environment through IOS/Android devices. Instructors can show learning material such as Google Docs and PowerPoint. The LIVE JustICE community will contain a community center, a tranquility center, and a message board. This will be an interactive community where participants will communicate in real-time on their mobile device or, if preferred, using their computer via text or audio chat. Access to LIVE will allow participants to utilize resources and links in the application, leave a message on the message board for the diabetes educators, or engage with other participants. Research team members will add and trial gaming activities to the VE during this feasibility study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Education
Description: See control group description above
Study: NCT04159467

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Floor Muscle Training
Description: 4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training
Description: 4 sets of 10 maximal perceived voluntary pelvic floor contractions sustained for 6 seconds, followed by 5 voluntary pelvic floor muscle contractions. The supervised 4 sets will be performed in 2 different positions (sitting and standing).
Study: NCT05267665

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Family Intervention (BFI)
Description: A 2-session psychoeducational and skills-based family intervention.
Study: NCT05870852

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: ESWT will be done once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT)
Description: ESWT will be done once a week for 4-5 minutes in total 3 times with ESWT. 2000 impulses will be applied on calcinosis with 2.4 bar pressure and 5.0 Hz frequency.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF
Description: PNF stretching techniques: It will be done with isometric contraction for 10 seconds against maximum resistance. 8-10 repetitions will be done. A 10-second listening interval will be left for active relaxation of the patient between the applications. PNF application will be done by the physiotherapist once a week. You will be asked to do the PNF stretching exercises taught once daily as a home program.
Study: NCT04119648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAMS-4Kids
Description: The Collaborative Assessment and Management of Suicidality (CAMS-Jobes, 2006; 2016) is an evidence-based, therapeutic framework for addressing suicide risk in the adult population. CAMS-4Kids, the research intervention used in this study, is a 10-session developmentally-sensitive adaptation of CAMS for children ages 5 - 11 years old.